200 related articles for article (PubMed ID: 37491794)
1. Lysosome-dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer.
Celada SI; Li G; Celada LJ; Lu W; Kanagasabai T; Feng W; Cao Z; Salsabeel N; Mao N; Brown LK; Mark ZA; Izban MG; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Wang X; Chen Z
Mol Oncol; 2023 Oct; 17(10):2126-2146. PubMed ID: 37491794
[TBL] [Abstract][Full Text] [Related]
2. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
3. SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.
Lu W; Liu S; Li B; Xie Y; Adhiambo C; Yang Q; Ballard BR; Nakayama KI; Matusik RJ; Chen Z
Oncotarget; 2015 Jan; 6(2):771-88. PubMed ID: 25596733
[TBL] [Abstract][Full Text] [Related]
4. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
5. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.
Li B; Lu W; Yang Q; Yu X; Matusik RJ; Chen Z
Prostate; 2014 Apr; 74(4):421-32. PubMed ID: 24347472
[TBL] [Abstract][Full Text] [Related]
6. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
7. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.
Adams EJ; Karthaus WR; Hoover E; Liu D; Gruet A; Zhang Z; Cho H; DiLoreto R; Chhangawala S; Liu Y; Watson PA; Davicioni E; Sboner A; Barbieri CE; Bose R; Leslie CS; Sawyers CL
Nature; 2019 Jul; 571(7765):408-412. PubMed ID: 31243370
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of FOXA1 with the malignancy and progression of prostate cancer].
Feng W; Zhang HB; Wang YM; Hu JL
Zhonghua Nan Ke Xue; 2015 May; 21(5):414-9. PubMed ID: 26117938
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
10. p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
Zhao H; Lu Z; Bauzon F; Fu H; Cui J; Locker J; Zhu L
Oncogene; 2017 Jan; 36(1):60-70. PubMed ID: 27181203
[TBL] [Abstract][Full Text] [Related]
11. FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype.
DeGraff DJ; Grabowska MM; Case TC; Yu X; Herrick MK; Hayward WJ; Strand DW; Cates JM; Hayward SW; Gao N; Walter MA; Buttyan R; Yi Y; Kaestner KH; Matusik RJ
Lab Invest; 2014 Jul; 94(7):726-39. PubMed ID: 24840332
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
13. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
14. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.
Yang G; Ayala G; De Marzo A; Tian W; Frolov A; Wheeler TM; Thompson TC; Harper JW
Clin Cancer Res; 2002 Nov; 8(11):3419-26. PubMed ID: 12429629
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression.
Su Y; Zhang Y; Zhao J; Zhou W; Wang W; Han B; Wang X
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3225-3243. PubMed ID: 34258652
[TBL] [Abstract][Full Text] [Related]
16. Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.
Arbini AA; Greco M; Yao JL; Bourne P; Marra E; Hsieh JT; di Sant'agnese PA; Moro L
Am J Pathol; 2011 May; 178(5):2367-76. PubMed ID: 21514447
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer.
Osei-Amponsa V; Buckwalter JM; Shuman L; Zheng Z; Yamashita H; Walter V; Wildermuth T; Ellis-Mohl J; Liu C; Warrick JI; Shantz LM; Feehan RP; Al-Ahmadie H; Mendelsohn C; Raman JD; Kaestner KH; Wu XR; DeGraff DJ
Oncogene; 2020 Feb; 39(6):1302-1317. PubMed ID: 31636388
[TBL] [Abstract][Full Text] [Related]
18. Genetic features of TP53 mutation and its downstream FOXA1 in prostate cancer.
Xu X; Xie L; Meng L; Geng S; Liu J; Cao X; Dong Z; Xing Z
Biosci Trends; 2022 Jul; 16(3):221-229. PubMed ID: 35768267
[TBL] [Abstract][Full Text] [Related]
19. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.
Gerhardt J; Montani M; Wild P; Beer M; Huber F; Hermanns T; Müntener M; Kristiansen G
Am J Pathol; 2012 Feb; 180(2):848-61. PubMed ID: 22138582
[TBL] [Abstract][Full Text] [Related]
20. NEDD4 triggers FOXA1 ubiquitination and promotes colon cancer progression under microRNA-340-5p suppression and ATF1 upregulation.
Yue M; Yun Z; Li S; Yan G; Kang Z
RNA Biol; 2021 Nov; 18(11):1981-1995. PubMed ID: 33530829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
